Veronika J Wirtz*, Hans V Hogerzeil*, Andrew L Gray*, Maryam Bigdeli, Cornelis P de Joncheere, Margaret A Ewen, Martha Gyansa-Lutterodt, Sun Jing, Vera L Luiza, Regina M Mbindyo, Helene Möller, Corrina Moucheraud, Bernard Pécoul, Lembit Rägo, Arash Rashidian, Dennis Ross-Degnan, Peter N Stephens,

Abstract Background Due to competing health priorities and limited resources, many low-income countries, even those with a high disease burden, are not able to introduce pneumococcal conjugate vaccines. Objective To determine the cost-utility of 10- and 13-valent pneumococcal conjugate vacci

Abstract Background The World Health Organization (WHO) has developed the Total System Effectiveness (TSE) framework to assist national policy-makers in prioritizing vaccines. The pilot was launched in Thailand to explore the potential use of TSE in a country with established governance struct

Abstract Background: Diarrhoea remains one of the top ten causes of under-five child morbidity in Bhutan, and rotavirus is a significant cause of child diarrhoeal hospitalisations. This study sought to determine the health outcomes, cost-effectiveness, and budget and human resource implications o

Beyond vaccine safety, efficacy and procurement lie licensing and delivery — nations must get ready. There are currently more than 40 candidate vaccines for COVID-19 in clinical evaluation, and more than 150 in preclinical development. Creating a safe and effective vaccine is akin to striking bas

Abstract Innovations in vaccine product attributes could play an important role in addressing coverage and equity (C&E) gaps, but there is currently a poor understanding of the full system impact and trade-offs associated with investing in such technologies, both from the perspective of natio

Summary The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 20

Abstract Real-world effectiveness studies are important for monitoring performance of COVID-19 vaccination programmes and informing COVID-19 prevention and control policies. We aimed to synthesise methodological approaches used in COVID-19 vaccine effectiveness studies, in order to evaluate which

The introduction of Coronavirus disease 2019 (COVID-19) vaccines urged all Thais to seek prevention of serious illness and death from COVID-19. However, immunocompromised individuals might not be able to achieve an efficient immune response from these vaccines. This study aimed to evaluate the cost-

Siriporn Pooripussarakul Arthorn Riewpaiboon David Bishai Sripen Tantivess Charung Muangchana บทคัดย่อ การนำวัคซีนใหม่เข้ามาใช้ขึ้นอยู่กับหลายปัจจัย ได้แก่ นโยบาย แนวทางปฏิบัติ และการประเมินทางเศรษฐศาสตร์ ผู้ที่เกี่ยวข้องต่างๆ จึงพิจารณาปัจจัยสำคัญที่แตกต่างกันไปในการนำวัคซีนใหม่เข้าสู่โครงก